Advertisement
Australia markets close in 5 hours 32 minutes

  • ALL ORDS

    7,810.00
    -88.90 (-1.13%)
     

  • ASX 200

    7,554.00
    -88.10 (-1.15%)
     

  • AUD/USD

    0.6413
    -0.0012 (-0.19%)
     

  • OIL

    82.50
    -0.23 (-0.28%)
     

  • GOLD

    2,390.20
    -7.80 (-0.33%)
     

  • Bitcoin AUD

    98,475.31
    +3,341.41 (+3.51%)
     

  • CMC Crypto 200

    1,303.23
    +417.69 (+46.73%)
     

  • AUD/EUR

    0.6027
    -0.0004 (-0.07%)
     

  • AUD/NZD

    1.0873
    -0.0002 (-0.02%)
     

  • NZX 50

    11,796.17
    -39.87 (-0.34%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • Hang Seng

    16,385.87
    +134.03 (+0.82%)
     

  • NIKKEI 225

    37,391.01
    -688.69 (-1.81%)
     

Acer Therapeutics to Virtually Present at Upcoming Investor Conferences

Acer Therapeutics Inc.
·2-min read

NEWTON, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a virtual corporate overview at upcoming investor conferences in September, including the LD Micro 500 Virtual Conference and the H.C. Wainwright 22nd Annual Global Investment Conference.

Acer Conference Presentation Details:

Conference:

LD Micro 500 Virtual Conference

Date:

Tuesday, September 1, 2020

Time:

3 p.m. Eastern Time

Conference:

H.C. Wainwright 22nd Annual Global Investment Conference

Date:

Tuesday, September 15, 2020

Time:

2:30 p.m. Eastern Time

More information on Acer presentations can be found in the “Events and Presentations” section of Acer’s website at https://www.acertx.com/investor-relations/events-presentations/.

ADVERTISEMENT

About Acer Therapeutics Inc.

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant for the treatment of induced Vasomotor Symptoms (iVMS). Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. For more information, visit www.acertx.com.

Investor Contact:
Hans Vitzthum
LifeSci Advisors
Ph: 617-430-7578
hans@lifesciadvisors.com

Jim DeNike
Acer Therapeutics Inc.
Ph: 844-902-6100
jdenike@acertx.com